YOU ARE HERE:
Changing treatments news
page  of 7
 
Headline
Date
  Second-line combinations fail twice as often as first-line ones in the first year
16.11.08
  If you can't switch, better to stay on failing treatment than stop it, studies show
14.11.08
  Darunavir European license extended to all treatment-experienced
30.10.08
  CD4 decline, death more likely if change from NNRTI regimen delayed
23.10.08
  Reduced dose atazanavir safe and effective in small Thai study
17.10.08
  Switching to AZT from d4T poses challenges in resource-limited settings
19.09.08
  Etravirine (Intelence) approved in Europe for treatment-experienced patients
02.09.08
  Uptake of second-line treatment `stagnant` in developing world
14.08.08
  Widespread NRTI and NNRTI resistance seen in Malawian patients failing first-line antiretroviral therapy
06.08.08
  US study confirms long-term use of AZT, d4T result in lipoatrophy
27.05.08
  Adherence predicts viral failure just as well as CD4 count change, South African study shows
20.05.08
  Does tenofovir increase the risk of efavirenz-associated liver side-effects?
09.05.08
  Dual class drug resistance present in two-thirds of South African HIV cohort on failing ART
05.05.08
  Clinical monitoring as effective as CD4 count and viral load for deciding when to switch to second-line ART in poor countries
25.04.08
  ART recommended for all with CD4 counts below 350, say South African doctors
17.04.08
  Start anti-HIV treatment with a CD4 cell count of 350 with efavirenz and Truvada, say draft British guidelines
01.04.08
  CROI: Risk of second virological failure has declined since 1996, but risk of death remains stable
07.02.08
  WHO expert panel wants fewer second-line ART choices
31.01.08
  Kaletra monotherapy studies yield conflicting results
28.01.08
  Less risk of AIDS for patients with low CD4 cell count and no treatment options who stay on failing therapy
25.01.08

page  of 7